Formulary Coverage of Brand-Name Adalimumab and Biosimilars Across Medicare Part D Plans
JAMA · 2024
DOI: 10.1001/jama.2024.8917 ↗Kurz gefasst
Fachartikel in der Zeitschrift JAMA, 2024. Verfasst von Matthew J Klebanoff und 3 weiteren Autor:innen. Beteiligte Einrichtung: Division of General Internal Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia. Hauptthemen laut MEDLINE: Adalimumab, Biosimilar Pharmaceuticals, Formularies as Topic, Insurance Coverage. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 6 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIA NIH HHS.
Abstract (Originalsprache)
This study examines formulary coverage of brand-name adalimumab and biosimilars across Medicare Part D plans.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Division of General Internal Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia.
- Leonard Davis Institute of Health Economics, University of Pennsylvania, Philadelphia.
- The University of Texas MD Anderson Cancer Center, Houston.
Förderung
- NIA NIH HHS
Zitieren
APA
Klebanoff, M. J., Li, P., Lin, J. K., & Doshi, J. A. (2024). Formulary Coverage of Brand-Name Adalimumab and Biosimilars Across Medicare Part D Plans. JAMA. https://doi.org/10.1001/jama.2024.8917
Vancouver
Klebanoff MJ, Li P, Lin JK, Doshi JA. Formulary Coverage of Brand-Name Adalimumab and Biosimilars Across Medicare Part D Plans. JAMA. 2024. doi:10.1001/jama.2024.8917
BibTeX
@article{Klebanoff2024,
author = {Klebanoff, Matthew J and Li, Pengxiang and Lin, John K and Doshi, Jalpa A},
title = {Formulary Coverage of Brand-Name Adalimumab and Biosimilars Across Medicare Part D Plans},
journal = {JAMA},
year = {2024},
doi = {10.1001/jama.2024.8917}
}
EUVIMED